Capital decision support
Forecast simulation for a $1B+ pharmaceutical acquisition
I designed scenario and simulation analysis spanning commercial, rollout, market, baseline, and upside assumptions to support the evaluation of a pharmaceutical acquisition valued above $1 billion.
Why it matters for you: the case needed interacting scenarios and explicit uncertainty rather than one deterministic forecast. The same discipline applies to launches, sales-force choices, licensing, and portfolio decisions.
